A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection (PREVENT-HD)

  • STATUS
    Recruiting
  • participants needed
    4000
  • sponsor
    Janssen Research & Development, LLC
Updated on 5 July 2022
diabetes
body mass index
fever
cancer
fatigue
myalgia
dyspnea
d-dimer
covid-19
PCR test
cough
ageusia
nasopharyngeal swab
coronavirus infection

Summary

The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) Infection.

Details
Condition Coronavirus Disease 2019 (COVID-19)
Treatment Placebo, Rivaroxaban, Standard of Care (SOC)
Clinical Study IdentifierNCT04508023
SponsorJanssen Research & Development, LLC
Last Modified on5 July 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note